In our cohort, considering the values at admission and the trend over the first 7 days, MR-proADM proved to have an adequate prognostic value in both areas of application (ICU and non-ICU patients), apparently showing a better prognostic performance than other ‘traditional’ inflammatory biomarker considered, such as CRP or procalcitonin, or other biomarkers used in COVID-19 patients, such as D-dimer, LDH and ferritin.30 The gene discussed is CRP; the disease is COVID-19.